Skip to main content
Clinical Trials/JPRN-UMIN000001478
JPRN-UMIN000001478
Completed
未知

A combination of cinacalcet with maxacalcitol for regression of moderate to advanced secondary hyperparathyroidism in patients on chronic hemodialysis - Combined therapy of cinacalcet with maxacalcitol for regression of secondary hyperparathyroidism

Kitano Hospital Division of Nephrology and Dialysis0 sites50 target enrollmentOctober 25, 2009

Overview

Phase
未知
Intervention
Not specified
Conditions
secondary hyperparathyroidism
Sponsor
Kitano Hospital Division of Nephrology and Dialysis
Enrollment
50
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 25, 2009
End Date
December 1, 2010
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Kitano Hospital Division of Nephrology and Dialysis

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\) Uncontrolled ischemic heart disease, heart failure, and arrhythmia 2\) Stroke within 6 months 3\) Peripheral artery didease of Fontaine 3 and 4 4\) Severe liver cirrhosis 5\) Malignancy within 3 years 6\) Uncontrolled phychosis 7\) Attendant for other clinical studies within 3 months 8\) Pregnant woman or man who wish for baby 9\) Unsuitable patients

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Cinacalcet for the treatment of hypercalcemia with persistent hyperparathyroidism in renal transplant recipients: a case siries study.Hypercalcemia with persistent hyperparathyroidism in renal transplant recipients.
JPRN-UMIN000003236St Marianna University15
Completed
Not Applicable
Cinacalcet and concurrent intravenous calcitriol for treatment of secondary hyperparathyroidism in dialysis patients compared with intravenous calcitriol alonesecondary hyperparathyroidism
JPRN-UMIN0000034381.Division of Internal medicine, Seseragi hospital 2.Department of Medicine & Biological Science Gunma University Graduate School of Medicine100
Completed
Phase 4
Efficacy and safety of treatment with Cinacalcet in patients with Primary Hyperparathyroidism due to a MEN-1 mutatiohyperactive parathyroid glandsprimary hyperparathyroidism1008362410033949
NL-OMON34871eids Universitair Medisch Centrum20
Active, not recruiting
Not Applicable
Assess the stability / benefit of Cinacalcet treatment over conventional therapy based on bone metabolism, arterial stiffness and vascular calcification in advanced chronic renal failureBone's disorders and mineral metabolism and vascular involvementMedDRA version: 16.1Level: PTClassification code 10051753Term: Vascular calcificationSystem Organ Class: 10047065 - Vascular disordersTherapeutic area: Body processes [G] - Metabolic Phenomena [G03]
EUCTR2013-002270-52-ESHospital Universitari de Girona Dr.Josep Trueta
Active, not recruiting
Not Applicable
Efficacy and safety of the calcimimetic Cinacalcet in the management of patients with Primary Hyperparathyroidism due to a MEN-1 mutation - Cinacalcet in MEN-I PHPTPatients with primary hyperparathyroidism due to a germline mutation in the MEN-1 geneMedDRA version: 12.1Level: LLTClassification code 10036693Term: Primary hyperparathyroidism
EUCTR2010-018861-53-NLeiden University Medical Center